Avalo Therapeutics Inc.

AVTX | NASDAQ

Price Alert Chart Builder DCF Calculator

$16.17

-$0.40 (-2.41%)

At close: Sep 21, 2026, 4:00 PM ET

$16.17

$0 (0.00%)

After-hours: Sep 21, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-2.41%

(1D)

Rating

Updated: Aug 26, 2026

33.5

Fundamentals Weak

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $849.99M

1D Range

15.92 16.54

52W Range

10.70 24.27

Valuation (TTM)

PE -3.41

PB 1.89

EV/EBITDA -4.50

Valuation (NTM)

Forward PE N/A

Forward PEG -0.86

Price Target $45.13

Cash Flow

FCF Yield -7.8%

SBC Adj. FCF Yield -9.8%

SBC Impact -24.9%

Margins

Gross Margin -16861.0%

Operating Margin -154844.1%

FCF Margin -112505.1%

Growth (CAGR)

Revenue 3Y | 5Y -84.8% | -60.9%

Dil EPS 3Y | 5Y 150.0% | 83.7%

FCF 3Y | 5Y -35.1% | -8.1%

Returns

ROA -20.4%

ROE -58.0%

ROIC -19.4%

Financial Health

Net Cash

$400.28M

Current Ratio 19.31

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical...

Sector Healthcare

Industry Biotechnology

Employees 33

IPO Date Oct 13, 2015

Website www.avalotx.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$46.50

Upside

+187.57%

Buy (7)

Hold (0)

Sell (0)

Analyst Details ➞